Revolution Medicines, Inc. (RVMD) Misses Q2 EPS by 9c, beats revenue

Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q2 EPS of ($0.92), $0.09 worse than the analyst estimate of ($0.83). Revenue for the quarter came in at $3.82 million versus the consensus estimate of $928.57 thousand.

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Goldman Sachs Downgrades Vonovia SE (VNA:DR) (VNNVF) to Neutral
• UBS Upgrades E.ON SE (EOAN:GR) (EONGY) to Buy